Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three non-steroidal anti-inflammatory drugs (NSAIDs): aspirin, diclofenac, and ibuprofen. Each drug works by inhibiting cyclooxygenase (COX) enzymes, which reduces the production of prostaglandins that cause pain, inflammation, and fever. However, this specific combination is not recommended for clinical use as taking multiple NSAIDs simultaneously significantly increases the risk of adverse effects, particularly gastrointestinal bleeding, cardiovascular complications, and kidney damage. Research indicates that diclofenac may be preferred over ibuprofen when combined with aspirin for thromboprophylaxis, as ibuprofen can interfere with aspirin's antiplatelet effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aspirin + diclofenac + ibuprofen.